WHO WE ARE

Mission

Ocular diseases, such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, are debilitating and can deprive people of their vision. 


Current treatments have limited durability and are unable to correct the underlying disease pathology resulting in an untenable treatment burden and failure to fully restore vision.

Our business is to develop safer, more efficacious, and longer-lasting therapeutics for ocular diseases.

 

THE APTITUDE VISION TEAM

Who’s Who

Scott-2015.jpg

SCOTT FERGUSON PHD

Co-Founder & CEO

For nearly a decade, Scott has driven the realization of innovative solutions to major problems in health care. Prior to Aptitude, Scott has played an active role in multiple life science ventures, pioneered technologies for personalized medicine, and authored several patents, and highly-city journal publications.

Jackson-2015.jpg

JACKSON GONG PHD

Co-Founder & COO

Trained in both life science research and management, Jackson brings to Aptitude both scientific and operational expertise. He has published 10+ peer-reviewed papers and co-invented several patents that serve as the foundation of Aptitude technology.

JP-2015.jpg

JP WANG PHD

Co-Founder & CTO

JP has focused his career on applying engineering principles to biological problems that promote scientific discovery and the development of new biomedical technologies and therapies. He has authored multiple peer-reviewed journal publications, and is the lead inventor of Aptitude’s revolutionary aptamer discovery technology.